SIGA Technologies, Inc. (SIGA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

SIGA Technologies, Inc. (SIGA) Healthcare & Pipeline Overview

SIGA Technologies, Inc. specializes in developing and commercializing pharmaceutical solutions for health security threats, primarily focused on its antiviral drug TPOXX for smallpox. With a strategic partnership with Cipla Therapeutics, SIGA aims to deliver sustained innovation in the antibacterial drug space, addressing critical biothreats within the healthcare sector.

What Is the Investment Thesis for SIGA?

SIGA Technologies presents an investment case centered on its unique position in the health security market, primarily driven by its smallpox antiviral drug, TPOXX. The company's revenue is largely dependent on government contracts for TPOXX procurement, making it sensitive to changes in government priorities and funding. A key value driver is the continued demand for TPOXX as a critical component of biodefense strategies. Growth catalysts include potential expansions into new geographic markets and the development of new applications for TPOXX or other antiviral drugs. However, investors should be aware of potential risks, including reliance on single product revenue, government contract renewals, and competition from alternative treatments. With a market capitalization of $218M and a gross margin of 61.8%, SIGA's financial performance is closely tied to its ability to secure and fulfill government contracts.

Based on FMP financials and quantitative analysis

SIGA Key Highlights

SIGA Technologies' lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease.

• The company has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
• SIGA's gross margin stands at 61.8%, indicating a strong ability to manage production costs relative to revenue.
• The company's market capitalization is $218M, reflecting its current valuation in the market.
• SIGA Technologies' dividend yield is 12.50%.

Who Are SIGA's Competitors?

SIGA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SIGA's Key Strengths?

Proprietary antiviral drug TPOXX for smallpox treatment.

• Established relationships with government agencies.
• Strategic partnership with Cipla Therapeutics.
• Expertise in health security and infectious diseases.

What Are SIGA's Weaknesses?

Reliance on a single product (TPOXX) for revenue.

• Dependence on government contracts.
• Small company size with limited resources.
• Profit Margin: -4311739.0%

What Could Drive SIGA Stock Higher?

Continued government stockpiling of TPOXX for biodefense.

• Potential expansion into new geographic markets.
• Development of new applications for TPOXX or other antiviral drugs.

What Are the Key Risks for SIGA?

Negative return on equity (-1.5%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Reliance on a single product (TPOXX) for revenue.
• Dependence on government contracts.
• Competition from alternative treatments.
• Changes in government priorities and funding.

What Are the Growth Opportunities for SIGA?

• Expansion into International Markets: SIGA has the opportunity to expand its market reach for TPOXX beyond the United States by targeting international governments and public health organizations. Many countries maintain strategic stockpiles of antiviral medications to prepare for potential outbreaks of infectious diseases, including smallpox. By securing contracts with these international entities, SIGA can diversify its revenue streams and reduce its reliance on the U.S. government. The global market for biodefense products is estimated to be worth billions of dollars, offering significant growth potential for SIGA.
• Development of New Antiviral Therapies: SIGA can leverage its expertise in antiviral drug development to create new therapies for other infectious diseases. By expanding its product pipeline, SIGA can address a broader range of public health threats and reduce its dependence on TPOXX. This could involve developing new antiviral drugs for diseases such as monkeypox, Ebola, or other emerging infectious diseases. The market for antiviral therapies is constantly growing, driven by the emergence of new viral threats and the increasing need for effective treatments.
• Strategic Partnerships and Acquisitions: SIGA can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. By partnering with other pharmaceutical companies or research institutions, SIGA can gain access to new technologies, expertise, and distribution channels. This could involve collaborating on the development of new antiviral therapies or acquiring companies with complementary products or technologies. Strategic partnerships and acquisitions can accelerate SIGA's growth and enhance its competitive position in the health security market.
• Government Stockpiling Initiatives: Ongoing government initiatives to stockpile antiviral medications for biodefense purposes represent a significant growth opportunity for SIGA. As governments around the world prioritize preparedness for potential outbreaks of infectious diseases, they are investing in stockpiles of critical medications like TPOXX. SIGA can capitalize on this trend by actively engaging with government agencies and public health organizations to secure contracts for TPOXX procurement. The continued focus on biodefense preparedness is expected to drive sustained demand for SIGA's products.
• Expanding TPOXX Applications: SIGA can explore new applications for TPOXX beyond its current indication for smallpox. While TPOXX is currently approved for the treatment of smallpox, it may have potential efficacy against other related viruses. SIGA can conduct research to investigate the potential of TPOXX for treating other orthopoxviruses, such as monkeypox. Expanding the approved indications for TPOXX would broaden its market potential and increase its value as a critical antiviral medication.

What Threats Does SIGA Face?

• Competition from alternative treatments.
• Changes in government priorities and funding.
• Regulatory challenges.
• Emergence of new infectious diseases.

What Are SIGA's Competitive Advantages?

• Proprietary antiviral drug TPOXX with limited competition.
• Established relationships with government agencies for biodefense contracts.
• Strategic partnerships for research and development.
• Expertise in developing and commercializing antiviral therapies.

What Does SIGA Do?

SIGA Technologies, Inc., incorporated in 1995 and headquartered in New York City, operates as a commercial-stage pharmaceutical company dedicated to addressing health security concerns, particularly within the infectious disease market. The company's flagship product is TPOXX (tecovirimat), an orally administered antiviral medication specifically designed for the treatment of smallpox, a disease caused by the variola virus. TPOXX has been a critical component of the U.S. government's biodefense strategy, securing contracts for its use in the event of a smallpox outbreak. SIGA's focus extends beyond smallpox, with a strategic partnership with Cipla Therapeutics aimed at developing and delivering innovative antibacterial drugs targeting various biothreats. This collaboration underscores SIGA's commitment to expanding its portfolio and addressing a broader range of infectious disease challenges. The company's business model revolves around securing government contracts and commercializing its products to protect against public health emergencies. With a relatively small team of 46 employees, SIGA operates with a lean structure, focusing on research, development, and strategic partnerships to maximize its impact in the health security market. SIGA's evolution has been marked by its dedication to addressing critical biodefense needs, positioning it as a key player in safeguarding public health against potential threats.

What Products and Services Does SIGA Offer?

• Develops and commercializes pharmaceutical solutions for health security threats.
• Focuses primarily on antiviral drugs for infectious diseases.
• Manufactures and distributes TPOXX, an oral antiviral drug for smallpox treatment.
• Engages in strategic partnerships to expand its product pipeline.
• Secures government contracts for the supply of biodefense medications.
• Conducts research and development to identify new antiviral therapies.
• Addresses public health emergencies related to infectious diseases.

How Does SIGA Make Money?

• Develops and manufactures antiviral drugs, primarily TPOXX.
• Secures contracts with government agencies for the supply of TPOXX.
• Partners with other pharmaceutical companies for research and development.
• Commercializes its products to protect against public health emergencies.

What Industry Does SIGA Operate In?

SIGA Technologies operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, regulatory scrutiny, and the constant need for innovation. The market for biodefense products, in particular, is driven by government spending and public health concerns. Companies like SIGA play a crucial role in developing and supplying treatments for potential bioterrorism threats. The competitive landscape includes other pharmaceutical companies focused on antiviral and antibacterial drugs, as well as government agencies and research institutions involved in biodefense research and development.

Who Are SIGA's Key Customers?

• U.S. government agencies, such as the Department of Health and Human Services.
• International governments and public health organizations.
• Strategic partners in the pharmaceutical industry.
• Entities responsible for biodefense and public health preparedness.

Over the past six months, SIGA Technologies, Inc. insiders filed 30 SEC Form 4 transactions — 15 sales and 15 purchases. On net that is roughly 192K shares acquired (about $240K) — insiders putting money in tends to read as conviction.

SIGA Technologies, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 13.11 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for SIGA Technologies, Inc. stands at -1.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.

SIGA Technologies, Inc. (SIGA) Valuation Context

Valued at $218M, SIGA is classified as a micro-cap stock. Relative to its peer group, SIGA's quantitative score of 35/100 is below the peer average of 51/100.

SIGA Revenue & Earnings Trend

In Q2 FY2026, SIGA generated $41.0M in top-line revenue, marking a sequential increase of 556.8%. The company recorded net income of $12.5M, with diluted EPS of $0.17. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, SIGA averaged $-0.01 in diluted EPS.

Company Profile

SIGA Technologies, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Diem Nguyen. SIGA has traded publicly since 1997.

SIGA Financials

SIGA Latest News

SIGA Analyst Consensus

SIGA MoonshotScore

Common Questions About SIGA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources